Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395129 | 0.80 | EGFR (0.41) | CHRNA7HTR3AMAP4K4EGFRKDR | |
| SCHEMBL17250007 | 0.79 | CHRNA7 (0.32) | CHRNA7HTR3AMAP4K4 | |
| SCHEMBL17250006 | 0.79 | CHRNA7 (0.33) | CHRNA7HTR3AMAP4K4EGFRKDR | |
| SCHEMBL24197718 | 0.76 | EGFR (0.35) | CHRNA7HTR3AEGFRKDR | |
| SCHEMBL24391780 | 0.69 | ACVRL1 (0.33) | — | |
| SCHEMBL12405880 | 0.67 | MAP4K4 (0.60) | MAP4K4EGFRKDR | |
| SCHEMBL21362878 | 0.67 | MAP4K4 (0.33) | MAP4K4 | |
| SCHEMBL24197721 | 0.66 | — | — | |
| SCHEMBL24392571 | 0.63 | EGFR (0.37) | MAP4K4EGFRKDR | |
| SCHEMBL24392136 | 0.62 | EGLN2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | CHRNA7 1881/4885HTR3A 3814/4885MAP4K4 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.